Company Overview and News
Despite the efforts of OPEC and Russia, and the prodding of President Trump, oil prices continue to hover above the $70 level, with West Texas Intermediate closing Friday at $71.01 a barrel and Brent North Sea Crude at $75.30. While oil traded down Monday morning, levels are still higher than anticipated when we started 2018. Production levels remain steady in the United States, but reserves are not being replenished as demand has increased.
As oil has recovered from its epic fall from above $100 to below $30 in 2014/15, many oil related stocks have also regained lost ground. The recovery in stocks, however has been far from even. Some, like Diamondback Energy (FANG) recovered to hit record highs, but others have still yet to recover at all. Transocean (RIG) is in that second group. That is for good reason, but it does leave plenty of room for a big jump, and a strong case can be made right now that one is coming.
Chicago, IL –July 5, 2018 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
CRR 6755 HP CVX FGELF STX BCEI SMCI FANG
Once it was the hottest oil and natural gas production region in the United States, and the top companies focused on the Permian Basin in West Texas and New Mexico performed well. Recently though, the ability to transport production has been hampered by pipeline capacity issues. As a result, some of the top Permian stocks have been hit hard, and investors are literally being offered some of the best entry points in years.
One stock that might be an intriguing choice for investors right now is Diamondback Energy, Inc. (FANG - Free Report) . This is because this security in the Oil and Gas - Exploration and Production - United States space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board.
GM.WS.A GM.WS.B GM.WS.C GM GM.WSB PII FANG
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET